TransMedics Group (NASDAQ:TMDX) Shares Gap Up – What’s Next?

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $64.05, but opened at $67.42. TransMedics Group shares last traded at $65.03, with a volume of 673,822 shares trading hands.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Canaccord Genuity Group decreased their target price on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Robert W. Baird dropped their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Oppenheimer restated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, TD Cowen reduced their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Price Performance

The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of 63.64 and a beta of 2.12. The stock’s 50 day simple moving average is $72.63 and its 200-day simple moving average is $119.17.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same period last year, the firm posted ($0.12) EPS. The company’s revenue was up 63.7% compared to the same quarter last year. On average, analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by insiders.

Institutional Trading of TransMedics Group

Hedge funds have recently modified their holdings of the company. USA Financial Formulas acquired a new stake in shares of TransMedics Group in the 3rd quarter valued at approximately $55,000. Quarry LP increased its stake in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares in the last quarter. National Bank of Canada FI increased its stake in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares in the last quarter. Farther Finance Advisors LLC increased its stake in TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares in the last quarter. Finally, Rakuten Securities Inc. bought a new stake in TransMedics Group during the 3rd quarter worth approximately $126,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.